title: Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies.
abstract: Variants of the envelope gene of the HIV-SF2 isolate of HIV-1 with deletions of one or more of the hypervariable domains of gp120 were produced in genetically engineered yeast as nonglycosylated denatured polypeptide analogs of gp120. Purified antigens were used to immunize experimental animals to determine whether the removal of hypervariable regions from this type of gp120 immunogen had any effect on (1) the ability of the antigen to elicit virus neutralizing antibodies; and (2) the isolate specificity of the neutralizing antibodies that were elicited. The results of these studies demonstrate that, in addition to the previously identified V3 domain, at least two other hypervariable regions in gp120 are capable of eliciting neutralizing antibodies in experimental animals. However, when all five of the hypervariable regions were deleted, the resulting antigen was no longer capable of eliciting neutralizing antibodies. Finally, the neutralizing antibodies elicited by all of these nonglycosylated antigens were effective against HIV-SF2, the isolate from which the antigens were derived, but were not able to neutralize two divergent isolates, HIV-BRU or HIV-Zr6.
authors.affiliation: Chiron Research Laboratories, Chiron Corporation, Emeryville, CA 94608.
authors.forename: N L
authors.initials: NL
authors.lastname: Haigwood
authors.forename: J R
authors.initials: JR
authors.lastname: Shuster
authors.forename: G K
authors.initials: GK
authors.lastname: Moore
authors.forename: H
authors.initials: H
authors.lastname: Lee
authors.forename: P V
authors.initials: PV
authors.lastname: Skiles
authors.forename: K W
authors.initials: KW
authors.lastname: Higgins
authors.forename: P J
authors.initials: PJ
authors.lastname: Barr
authors.forename: C
authors.initials: C
authors.lastname: George-Nascimento
authors.forename: K S
authors.initials: KS
authors.lastname: Steimer
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002478:Cells, Cultured; D005260:Female; D006168:Guinea Pigs; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D009154:Mutation; D009500:Neutralization Tests; D011994:Recombinant Proteins / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines